通过"薄标签"批准的第一个仿制药的频率,2021年至2023年
Therese J Ziaks1, Chukwubuikem M Akanegbu2, Alexander C Egilman3
1Yale School of Public Health, New Haven, CT.
Journal of managed care & specialty pharmacy
|March 28, 2025
概括
从2021年到2023年,用于仿制药批准的薄标签的使用量每年都在下降. 这一趋势表明,在2021年法院的一项关键裁决之后,仿制药对通用药的竞争可能产生抑制作用.
科学领域:
- 制药政策 制药政策
- 药品定价和市场准入问题
- 药品领域的知识产权法
背景情况:
- 品牌药品制造商利用市场独家权和专利,包括使用方法专利,来扩大其市场保护.
- 美国食品和药物管理局 (FDA) 允许仿制药制造商使用"薄标签"途径,不包括专利指示,以促进早期进入市场.
研究的目的:
- 分析通用处方药制造商利用瘦身标签途径的最新趋势.
- 调查2021年GlaxoSmithKline诉Teva联邦法院决定对仿制药制造商采用瘦身标签的影响.
主要方法:
- 从2021年到2023年,评估FDA批准的第一批使用瘦身标签的仿制药处方的比例.
- 审查GlaxoSmithKline诉Teva裁决后使用瘦身标签的变化,这增加了仿制药制造商的法律风险.
主要成果:
- 从2021年到2023年,有42.9%的易受影响的品牌药物有瘦弱标签的通用处方.
- 瘦身标签的通用处方的比例每年都在下降:2021年56%,2022年43%,2023年20% .
结论:
- 在研究期 (2021) 早期的瘦身标签率与之前的发现一致 (2015-2019年为43%).
- 瘦身标签的年度使用量下降表明,2021年法院的决定可能会阻碍仿制药制造商进入市场,可能会推迟竞争.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
651
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
651
Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Drug Classes and Categories
1.8K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
1.8K
Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Bioequivalence: Overview
874
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
874


